Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.53 |
| ▸ | VEGFA | P15692 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513364 | 0.83 | MAPT (0.70) | EGLN1VEGFAPKMPOLBMAPT | |
| SCHEMBL19513455 | 0.82 | MAPT (0.53) | EGLN1VEGFAPKMPOLBMAPT | |
| SCHEMBL16509736 | 0.82 | BRD4 (0.56) | EGLN1VEGFAPKMPOLBMAPT | |
| SCHEMBL29348731 | 0.81 | HDAC3 (0.52) | EGLN1VEGFAPKMPOLBMAPT | |
| SCHEMBL4992841 | 0.80 | BRD4 (0.56) | EGLN1VEGFAMAPTTP53LMNA | |
| SCHEMBL4683045 | 0.79 | MAPT (0.46) | EGLN1VEGFAPOLBMAPTTP53 | |
| SCHEMBL12599486 | 0.78 | EGLN1 (0.71) | EGLN1PKMPOLBMAPTTP53 | |
| SCHEMBL14221240 | 0.78 | LMNA (0.57) | EGLN1VEGFAPKMPOLBMAPT | |
| SCHEMBL17540820 | 0.78 | POLB (0.54) | EGLN1VEGFAPOLBMAPT | |
| SCHEMBL3696370 | 0.78 | PKM (0.51) | EGLN1VEGFAPKMPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | EGLN1 312/4885VEGFA 2862/4885PKM 867/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | EGLN1 312/4885VEGFA 2862/4885PKM 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.